Search Results - "Harris, L.N."

Differences between African American (AA) and Caucasian (C) Patients Treated With Conservative Surgery and Radiation Therapy (CS+RT) for Early Stage Breast Cancer by Moran, M.S, Harris, L.N, Haffty, B.G

Get full text

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

“…The National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic…”
Get full text

530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H by Janku, F., Wei, Z., Davies, M.A., Mitchell, E.P., Wright, J.J., Doyle, L.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B., Arteaga, C.L., Harris, L.N., O'Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q: Annals of Oncology 30 (2019) 1821–1830 by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K by Kalinsky, K., Zihan, W., McCourt, C., Mitchell, E.P., Wright, J.J., Doyle, L.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.A., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade by Kim, Y J, Greer, C B, Cecchini, K R, Harris, L N, Tuck, D P, Kim, T H

“…Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to…”
Get full text

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A by Reckamp, K., Song, Z., Gettinger, S., Mitchell, E.P., Wright, J.J., Moscow, J.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V by Gien, L., Song, Z., Poklepovic, A., Collisson, E.A., Mitchell, E.P., Zweibel, J.A., Harris, P., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

Get full text

439: Pass it on by Harris, L.N, Guess, C.W, Frey, M.A, Kurtzberg, J

Get full text

Pleistocene glaciations and contemporary genetic diversity in a Beringian fish, the broad whitefish, Coregonus nasus (Pallas): inferences from microsatellite DNA variation by HARRIS, L.N, TAYLOR, E.B

“…The contemporary distribution of genetic variation within and among high latitude populations cannot be fully understood without taking into consideration how…”
Get full text

Critical care usage after major gastrointestinal and liver surgery: a prospective, multicentre observational study

“…Patient selection for critical care admission must balance patient safety with optimal resource allocation. This study aimed to determine the relationship…”
Get more information

NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss by Janku, F, Jegede, O, Puhalla, S L, Konstantinopoulos, P, Meric-Bernstam, F, Mitchell, E P, Zwiebel, J A, McShane, L M, Li, S, Rubinstein, L V, Doyle, L A, Patton, D, Conley, B A, O'Dwyer, P J, Harris, L N, Arteaga, C, Williams, P M, Hamilton, S R, Chen, A P, Flaherty, K T

Get full text

Phase I study of Doxil and vinorelbine in metastatic breast cancer by BURSTEIN, H. J, RAMIREZ, M. J, PETROS, W. P, CLARKE, K. D, WARMUTH, M. A, MARCOM, P. K, MATULONIS, U. A, PARKER, L. M, HARRIS, L. N, WINER, E. P

“…Vinorelbine and Doxil (liposomal doxorubicin) are active chemotherapeutic agents in metastatic breast cancer. A phase I study was designed to evaluate…”
Get full text

Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage [formula omitted] breast cancer by Burstein, H.J, Harris, L.N, Kaelin, C.M, Parker, L.M, Kuter, I, Gadd, M.A, Borges, V, Bunnell, C.A, Smith, B.L, Winer, E.P

Get full text

First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer by Vogel, C., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., Shak, S., Stewart, S.J.

Get full text

397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer by Harris, L.N., Burstein, H., Gelman, R., Freidman, P., Kuter, I., Borges, V., Kaelin, C., Bellon, J., Smith, D., Winer, E.

Get full text

Can we increase survival in breast cancer with innovative applications of conventional drugs? by Swain, S M, Harris, L N

Get more information

Mass spectrometry in structural and stereochemical problems. CXXXII. Electron impact induced alkyl and aryl rearrangements in .alpha.,.beta.-unsaturated cyclic ketones by Harris, Roger L. N, Komitsky, Frank, Djerassi, Carl

Get full text

Mass spectrometry in structural and stereochemical problems. CXXXIV. Electron impact induced alkyl and aryl rearrangements in .alpha.-arylidene cyclic ketones by Harris, Roger L. N, Komitsky, Frank, Djerassi, Carl

Get full text